RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Nivolumab in second line non-small cell lung cancer - Comparing real-world outcomes in England to CheckMate (CM) 017 and 057
Popat, S., Tanna, N., Hartridge-Lambert, S., Kiff, C., Sowdani, A., Rothwell, B., Henrik-Brodtkorb, T., Ling, C., Smittenaar, R., Bomb, M., Turnbull, A., & Lawton, S. (2021). Nivolumab in second line non-small cell lung cancer - Comparing real-world outcomes in England to CheckMate (CM) 017 and 057. Journal of Thoracic Oncology, 16(3), S637-S638.